Aytu Biopharma (AYTU) Debt to Equity: 2009-2025
Historic Debt to Equity for Aytu Biopharma (AYTU) over the last 11 years, with Sep 2025 value amounting to $1.09.
- Aytu Biopharma's Debt to Equity rose 121.72% to $1.09 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.40, marking a year-over-year increase of 71.67%. This contributed to the annual value of $1.05 for FY2025, which is 119.75% up from last year.
- As of Q3 2025, Aytu Biopharma's Debt to Equity stood at $1.09, which was up 3.84% from $1.05 recorded in Q2 2025.
- Aytu Biopharma's 5-year Debt to Equity high stood at $1.09 for Q3 2025, and its period low was $0.11 during Q1 2021.
- In the last 3 years, Aytu Biopharma's Debt to Equity had a median value of $0.49 in 2024 and averaged $0.60.
- As far as peak fluctuations go, Aytu Biopharma's Debt to Equity soared by 1,084.98% in 2021, and later declined by 7.66% in 2024.
- Aytu Biopharma's Debt to Equity (Quarterly) stood at $0.16 in 2021, then spiked by 207.11% to $0.48 in 2022, then rose by 1.63% to $0.49 in 2023, then declined by 6.62% to $0.45 in 2024, then soared by 121.72% to $1.09 in 2025.
- Its last three reported values are $1.09 in Q3 2025, $1.05 for Q2 2025, and $0.56 during Q1 2025.